{"id":51660,"date":"2022-12-07T12:02:41","date_gmt":"2022-12-07T11:02:41","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\/"},"modified":"2022-12-07T12:02:41","modified_gmt":"2022-12-07T11:02:41","slug":"metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\/","title":{"rendered":"Metrion Biosciences and The KCNC1 Foundation Collaborate on Development of New Ion Channel Modulators for Ultra-Rare Genetic Disorder"},"content":{"rendered":"
\n

\nResearch targeted at identifying novel inhibitors or activators of Kv3.1 mutation<\/i>\n<\/p>\n

CAMBRIDGE, England & TORONTO, Canada–(BUSINESS WIRE)–Metrion Biosciences Limited (\u201cMetrion\u201d), the specialist ion channel contract research and drug discovery company, and The KCNC1 Foundation, a not-for-profit organisation focused on the development of a treatment for an ultra rare genetic disorder, today announced a collaboration to progress a hit identification research project for small molecule modulators of the potassium ion channel Kv<\/sub>3.1, targeting KCNC1-related disorders.\n<\/p>\n

<\/a><\/p>\n

\nVariants of the KCNC1 gene impact Kv<\/sub>3.1 potassium channel function, resulting in neurodevelopmental disorders which can include progressive myoclonic epilepsy (PME) and developmental epileptic encephalopathy (DEE). Symptoms of KCNC1 disorder include seizures during infancy, vision impairment, developmental delay, intellectual disability and many others. The collaboration is focused on the identification of small molecule modulators of the variant potassium ion channel, Kv<\/sub>3.1 as a potential therapeutic strategy for KCNC1-related disorders, identified as being the cause of KCNC1 related DEE. Metrion will develop cell lines for both wild type and variant Kv<\/sub>3.1, to establish a fluorescence-based screen using FLIPR\u00ae<\/sup> Penta, a high-throughput cellular screening system. The high-throughput screen will then be used to identify novel inhibitors or activators of Kv<\/sub>3.1 mutant channels.\n<\/p>\n

\nThe KCNC1 Foundation was created by the parents of a child diagnosed with KCNC1-related DEE to support research aimed at accelerating the development of a cure, as well as to raise awareness to identify and connect patients and provide support for families.\n<\/p>\n

\n\u201c\u201cWe are very excited to collaborate with Metrion on the possibility of identifying a potential therapeutic for children with KCNC1-related disorder. This is our first step of many to address the pathophysiology of the disorder, to give individuals suffering the opportunity to reach their full potential.\u201d <\/i>Stephanie Telesca, Co-Founder of The KCNC1 Foundation, commented.<\/b> \u201cWe welcome any contributions toward The KCNC1 Foundation<\/a> as we work hard to pave a path towards a cure.\u201d<\/i>\n<\/p>\n

\nDr Andrew Southan, Metrion\u2019s Chief Executive, said: <\/b>\u201cI would like to thank The KCNC1 Foundation for choosing Metrion to progress this discovery research programme. Our team looks forward to helping the Foundation accomplish its goal to deliver efficacious treatments to patients as quickly as possible.\u201d<\/i>\n<\/p>\n

\nFor more information, please visit www.metrionbiosciences.com<\/a> and www.kcnc1.org<\/a>.\n<\/p>\n

\nDonations to The KCNC1 Foundation can be made through gofundme<\/a> or, for those in the USA, through the organisation\u2019s fiscal sponsor The Rare Village<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia contact:<\/b>
Katie Odgaard
\n
Zyme Communications
\n
E-mail: katie.odgaard@zymecommunications.com<\/a>
Tel: +44 (0)7787 502 947\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Research targeted at identifying novel inhibitors or activators of Kv3.1 mutation CAMBRIDGE, England & TORONTO, Canada–(BUSINESS WIRE)–Metrion Biosciences Limited (\u201cMetrion\u201d), the specialist ion channel contract research and drug discovery company, and The KCNC1 Foundation, a not-for-profit organisation focused on the development of a treatment for an ultra rare genetic disorder, today announced a collaboration to … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51660","6":"format-standard","7":"category-industry"},"yoast_head":"\nMetrion Biosciences and The KCNC1 Foundation Collaborate on Development of New Ion Channel Modulators for Ultra-Rare Genetic Disorder - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Metrion Biosciences and The KCNC1 Foundation Collaborate on Development of New Ion Channel Modulators for Ultra-Rare Genetic Disorder - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Research targeted at identifying novel inhibitors or activators of Kv3.1 mutation CAMBRIDGE, England & TORONTO, Canada–(BUSINESS WIRE)–Metrion Biosciences Limited (\u201cMetrion\u201d), the specialist ion channel contract research and drug discovery company, and The KCNC1 Foundation, a not-for-profit organisation focused on the development of a treatment for an ultra rare genetic disorder, today announced a collaboration to ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-07T11:02:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221207005430\/en\/1657791\/21\/Metrion_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Metrion Biosciences and The KCNC1 Foundation Collaborate on Development of New Ion Channel Modulators for Ultra-Rare Genetic Disorder\",\"datePublished\":\"2022-12-07T11:02:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\\\/\"},\"wordCount\":429,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221207005430\\\/en\\\/1657791\\\/21\\\/Metrion_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\\\/\",\"name\":\"Metrion Biosciences and The KCNC1 Foundation Collaborate on Development of New Ion Channel Modulators for Ultra-Rare Genetic Disorder - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221207005430\\\/en\\\/1657791\\\/21\\\/Metrion_Logo.jpg\",\"datePublished\":\"2022-12-07T11:02:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221207005430\\\/en\\\/1657791\\\/21\\\/Metrion_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221207005430\\\/en\\\/1657791\\\/21\\\/Metrion_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Metrion Biosciences and The KCNC1 Foundation Collaborate on Development of New Ion Channel Modulators for Ultra-Rare Genetic Disorder\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Metrion Biosciences and The KCNC1 Foundation Collaborate on Development of New Ion Channel Modulators for Ultra-Rare Genetic Disorder - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\/","og_locale":"en_US","og_type":"article","og_title":"Metrion Biosciences and The KCNC1 Foundation Collaborate on Development of New Ion Channel Modulators for Ultra-Rare Genetic Disorder - Pharma Trend","og_description":"Research targeted at identifying novel inhibitors or activators of Kv3.1 mutation CAMBRIDGE, England & TORONTO, Canada–(BUSINESS WIRE)–Metrion Biosciences Limited (\u201cMetrion\u201d), the specialist ion channel contract research and drug discovery company, and The KCNC1 Foundation, a not-for-profit organisation focused on the development of a treatment for an ultra rare genetic disorder, today announced a collaboration to ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-07T11:02:41+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221207005430\/en\/1657791\/21\/Metrion_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Metrion Biosciences and The KCNC1 Foundation Collaborate on Development of New Ion Channel Modulators for Ultra-Rare Genetic Disorder","datePublished":"2022-12-07T11:02:41+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\/"},"wordCount":429,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221207005430\/en\/1657791\/21\/Metrion_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\/","url":"https:\/\/pharma-trend.com\/en\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\/","name":"Metrion Biosciences and The KCNC1 Foundation Collaborate on Development of New Ion Channel Modulators for Ultra-Rare Genetic Disorder - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221207005430\/en\/1657791\/21\/Metrion_Logo.jpg","datePublished":"2022-12-07T11:02:41+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221207005430\/en\/1657791\/21\/Metrion_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221207005430\/en\/1657791\/21\/Metrion_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/metrion-biosciences-and-the-kcnc1-foundation-collaborate-on-development-of-new-ion-channel-modulators-for-ultra-rare-genetic-disorder\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Metrion Biosciences and The KCNC1 Foundation Collaborate on Development of New Ion Channel Modulators for Ultra-Rare Genetic Disorder"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51660"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51660\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}